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Abstract
Background: Clostridium difficile is a bacterium which can infect various animal
species, including humans. Infection with this bacterium is a leading
healthcare-associated illness. A better understanding of this organism and the
relationship between its genotype and phenotype is essential to the search for an
effective treatment. Genome-scale metabolic models contain all known
biochemical reactions of a microorganism and can be used to investigate this
relationship.
Results: We present icdf834, an updated metabolic network of C. difficile that
builds on iMLTC806cdf and features 1227 reactions, 834 genes, and 807
metabolites. We used this metabolic network to reconstruct the metabolic
landscape of this bacterium. The standard metabolic model cannot account for
changes in the bacterial metabolism in response to different environmental
conditions. To account for this limitation, we also integrated transcriptomic data,
which details the gene expression of the bacterium in a wide array of
environments. Importantly, to bridge the gap between gene expression levels and
protein abundance, we accounted for the synonymous codon usage bias of the
bacterium in the model. To our knowledge, this is the first time codon usage has
been quantified and integrated into a metabolic model. The metabolic fluxes
were defined as a function of protein abundance. To determine potential
therapeutic targets using the model, we conducted gene essentiality and
metabolic pathway sensitivity analyses and calculated flux control coefficients.
We obtained 92.3% accuracy in predicting gene essentiality when compared to
experimental data for C. difficile R20291 (ribotype 027) homologs. We validated
our context-specific metabolic models using sensitivity and robustness analyses
and compared model predictions with literature on C. difficile. The model
predicts interesting facets of the bacterium’s metabolism, such as changes in the
bacterium’s growth in response to different environmental conditions.
Conclusions: After an extensive validation process, we used icdf834 to obtain
state-of-the-art predictions of therapeutic targets for C. difficile. We show how
context-specific metabolic models augmented with codon usage information can
be a beneficial resource for better understanding C. difficile and for identifying
novel therapeutic targets. We remark that our approach can be applied to
investigate and treat against other pathogens.
Keywords: Clostridium difficile; metabolic networks; metabolic pathways;
metabolic modeling; genome scale modeling; flux balance analysis; sensitivity
analysis; antibiotic resistance
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Introduction
Clostridium difficile is a gram-positive, spore-forming, anaerobic bacterium, which
infects or colonizes various animal species. Clinical manifestations in humans range
from asymptomatic colonization to mild diarrhea, pseudomembranous colitis, and
death [1]. Infection by this bacterium is associated not only with significant patient
morbidity and mortality, but also with a large economic burden for healthcare
systems [2]. The primary risk factor for development of C. difficile infection among
hospitalized patients is antibiotic use, which promotes toxicogenic C. difficile strains
to proliferate, produce toxins, and induce disease [3]. Infection by this bacterium
is most commonly associated with antibiotics such as clindamycin and amoxicillin
[4]. Current recommendations for treatment of C. difficile infection (CDI) call for
other antibiotics, such as metronidazole for mild infection cases and vancomycin
for more severe cases [5]. The emergence of hypervirulent and antibiotic-resistant
strains of this bacterium has motivated the search for novel methods of treating
CDI. One method involves searching the bacterial central metabolic pathways for
drug targets to create the next generation of antibiotics [6].
The quest to better understand this bacterium and identify novel drug targets
against it can benefit vastly from a model of the genotype-phenotype relationship
of its metabolism. Methods to model the genotype-phenotype relationship range
from stochastic kinetic models [7] to statistical Bayesian networks [8, 9]. Kinetic
models are limited as extensive experimental data is required to determine the
rate laws and kinetic parameters of biochemical reactions. An alternative to kinetic
models is metabolic modeling, which has been used to depict a range of cell types
without the need for difficult-to-measure kinetic parameters [9]. Metabolic models
have been able to predict cellular functions, such as cellular growth capabilities on
various substrates, effect of gene knockouts at genome scale [10], and adaptation
of bacteria to changes in their environment [11]. Metabolic models require a well-
curated genome-scale metabolic network of the cell. Such networks contain all the
known metabolic reactions in an organism, along with the genes that encode each
enzyme involved in a reaction. The networks are constructed based on genome
annotations, biochemical characterizations, and published literature on the target
organism. The different scopes of such networks include metabolism, regulation,
signaling, and other cellular processes [10].
Despite the success of metabolic modeling in capturing large-scale biochemical
networks, the approach is limited as it describes cellular phenotype simply in
terms of biochemical reaction rates and is thereby disconnected from other biolog-
ical processes that impact phenotype. Moreover, metabolic models cannot account
for changes in the metabolism of the bacterium in response to different environ-
mental conditions. Recent advances in the omic technologies, such as genomics
(genes), transcriptomics (mRNA), and proteomics (proteins), have enabled quan-
titative monitoring of the abundance of biological molecules at various levels in a
high-throughput manner. Integration of transcriptomic data has been shown to be
effective in improving metabolic model predictions of cellular behavior in different
environmental conditions [12].
Here we present an integrated model of the metabolism of C.difficile strain 630.
We expanded the network iMLTC806cdf [13] with regards to various pathways,
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such as fatty acid, glycerolipid, and glycerophospholipid metabolism. Fatty acids
are not only important components of bacterial cell membranes but they are also
important intermediate metabolites in the production of vitamins, lipid A, and
quorum sensing molecules [14]. The metabolism of phospholipids is also of interest
as these compounds have been found to be closely tied to the growth phase in
bacteria such as Bacillus subtilis [15, 16].
To bridge the gap between gene expression data and protein abundance, we ac-
counted for the codon usage bias of the bacterium. During translation of a mRNA
to a protein, the information contained in the form of nucleotide triplets (codons) in
the RNA is decoded to derive the amino acid sequence of the resulting protein. Most
amino acids are coded by two to six synonymous codons. These codons, which code
for the same amino acid, are surprisingly used differentially in protein-encoding se-
quences [17]. The codon usage has been found to alter the translation time and the
abundance of the resulting protein [18, 19]. To our knowledge, this is the first time
codon usage has been quantified and incorporated into a genome-scale metabolic
reconstruction.
We used the modified network and flux balance analysis [20] to simulate the
steady-state metabolism of the bacterium. To understand the behavior of the bac-
terium in different environments, we integrated gene expression data. We incorpo-
rated the codon usage of the bacterium to bridge the gap between gene expression
levels and protein abundance in the model. We then validated our metabolic models
against the literature on the bacterium. Following this validation process, we used
our models to identify potential drug targets. Essential genes have been previously
proposed as potential therapeutic targets. [13]. We propose an additional method
of predicting therapeutically-relevant genes through metabolic pathway sensitivity
analysis and calculation of flux control coefficients. The choice of gene to target
can be further refined by eliminating genes with a human homolog to reduce the
off-target effects of the selected drug [13].
Methods
Construction and validation of the metabolic model
icdf834: an expansion of the iMLTC806cdf network
In modifying the iMLTC806cdf network [13], we consulted KEGG [21] and incorpo-
rated some of the output from the review and curation of the MetaCyc [22] database
for C. difficile, which was released on March 20, 2015. During curation, we manu-
ally considered the directionality and gene-reaction associations of each reaction in
the existing network. We also manually expanded the existing network according
to the procedure specified by Thiele et al. in [23]. We supported additions to the
network with published literature on the bacterium. For example, the fatty acid
profile found in Clostridium difficile is mostly dominated by C16:0, C16:1, C18:1,
and C18:0 [24]. The major phospholipid types in this bacterium are phosphatidyl-
glycerol analogs, with PG(31:2), PG(32:1), PG(33:2), PG(33:1) constituting the
majority of these species [24]. Our modified network icdf834 modifies and expands
pathways concerning lipid metabolism in the existing network, such as those where
compounds and reactions involved had been grouped together. By expanding the
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metabolism of the bacterium, we can also account for the wide array of fatty acids
C. difficile can metabolize from its environment. This can provide important in-
sights as many Gram-positive bacteria have been found to be able to incorporate
and metabolize extracellular fatty acids [25]. When defining metabolic pathways in
the expanded network, we used KEGG pathway identifiers so to remain consistent
with the conventions employed in iMLTC806cdf [13].
The lipid component of the biomass equation of iMLTC806cdf had been obtained
from the metabolic network of Staphylococcus aureus [26], where lipid compounds
had been lumped together. There is a paucity of analyses on the chemical content of
C. difficile’s biomass. Therefore, upon increasing the granularity of the network, we
assumed coefficients from the biomass equation of the iBsu1103 metabolic network
developed for Bacillus subtilis, where these lumped lipid and teichoic acid species
have been replaced by explicit species.
Constraint-based reconstruction and modeling approach
One constraint-based method for simulating the metabolic steady-state of a cell is
flux-balance analysis (FBA), which can be used to analyze the metabolic network
solely on the basis of systemic mass-balance and reaction capacity constraints. FBA
simulations have been able to capture microorganism growth, nutritional resource
consumption, and waste-product secretion rates of various cell types [27].
The first step of FBA involves representing the metabolic network in the form
of a numerical matrix S of size (m × n). This matrix contains the stoichiometric
coefficients of each of the m metabolites in the n different reactions. In the matrix,
each row represents one unique metabolite and each column represents one reaction.
The stoichiometric matrix helps enforce a mass balance constraint on the system.
The mass balance on the cell for i=1,...,m metabolites and j =1,...,n reactions con-
strains the metabolite concentrations xi, as shown in Equation 1, where vj is the
flux through reaction j.
dxi
dt
=
n∑
j=1
Sijvj , i = 1, ...,m. (1)
Under the steady state assumption dxidt = 0,∀i, the total amount of any compound
being produced equals the total amount being consumed:
n∑
j=1
Sijvj = 0, i = 1, ...,m. (2)
In most metabolic models, there are more reactions than there are compounds
[20]. Because there are more unknown variables than equations (n>m), any v that
satisfies Equation 2 is considered to be in the null space of S.
FBA can be used to find and determine points within the solution space that are
most representative of the biological system using linear programming methods.
Studies have revealed that metabolic fluxes in microorganisms are best predicted
by maximizing the cellular objectives of growth [27]. To determine the point corre-
sponding to the maximum growth rate within the constrained space, the objective
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function shown in Equation 3 was maximized:
f(v) = cT v, (3)
where c is a vector of weights and indicates how much each reaction flux contributes
to the biomass objective function. The maximum growth rate can be achieved by
determining the flux distribution v that results in maximal biomass flux. Additional
constraints can be added through the upper bound vUj and the lower bound v
L
j for
the flux vj . These bounds mandate the minimum and maximum fluxes allowed for
a certain reaction and further decrease the space of allowable flux distributions for
the relevant system. The mathematical representation of the metabolic reactions,
the objective function, and the capacity constraints define a linear system as shown
in Equation 4.
max cT v
subject to Sv = 0
vLj ≤ vj ≤ vUj , j = 1, . . . , n.
(4)
The model fluxes are usually given units of mmol/gDW · h, where gDW is the
dry weight of cell mass in grams and h is the reaction time in hours. The bounds
enforce thermodynamic constraints by dictating whether reactions are reversible
or irreversible. The lower and upper flux bounds were arbitrarily chosen to be -
10 mmol/gDW · h and 10 mmol/gDW · h for reversible reactions. For irreversible
reactions, vLj was chosen to be 0 mmol/gDW ·h and vUj was set to 10 mmol/gDW ·h.
For our analysis, we used the COBRA toolbox 2.0 [28] in Matlab (version R2015b,
Mathworks, Inc.).
Multi-objective optimization in metabolic models
One limitation of using only biomass as the objective is that goals in metabolism are
often different and simultaneously competing so the scalar notion of “optimality”
does not hold; examples of such trade-offs include maximizing energy production
while minimizing protein costs [29]. Moreover, the biomass objective vector is usu-
ally perpendicular to one of the surfaces of the solution space of the FBA problem.
Consequently, biomass maximizing flux states are usually degenerate; there exist
multiple flux distributions that yield the same maximal biomass value [30]. To
choose between the various flux distributions, additional criteria must be consid-
ered. For these reasons, we modeled metabolism as a multiobjective phenomenon.
By modeling the metabolism of bacterium as a multi-objective problem, we address
a conflict problem whereby maximizing one objective (eg. biomass) might involve
a trade-off in the other objective (eg. intracellular flux); cells are thought to face a
trade-off that is described by the set of Pareto-optimal solutions. We used a multi-
objective optimization approach to address the z objectives, as shown in Equation
5.
max f(v) = (f1(v), f2(v), ..., fz(v))
subject to Sv = 0
vLj ≤ vj ≤ vUj , j = 1, . . . , n.
(5)
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Note that, without loss of generality, we assumed that all the functions have to be
maximized since minimizing a function f(v) is equivalent to maximizing −f(v).
Various works have attempted to systematically evaluate the ability of different
objectives functions to reliably predict intracellular flux [31, 32]. According to their
findings, bacterial metabolism can be better described by the objective of maxi-
mization of biomass or ATP production paired with the objective of minimization
of intracellular flux [32]. Introducing the minimization of intracellular flux as a sec-
ondary objective allows for economic allocation of resources by the bacterium by
selecting for metabolic routes that contain the fewest number of steps [33]. Thus,
for our analyses we used maximization of biomass, along with minimization of in-
tracellular flux as our objectives.
In a maximization multi-objective problem, a vector that is part of the feasible
space is considered to be Pareto-optimal if all other vectors have the same or a lower
value for at least one of the objective functions. Therefore, a Pareto-optimal solution
is found when there exists no other feasible solution which would increase one
objective without decreasing another objective. The set of Pareto-optimal solutions
constitutes the Pareto-optimal front [34]. In the absence of additional information,
no one Pareto-optimal solution can be said to be better than the other; higher-level
information is required to choose one of the solutions [35].
As proposed by Costanza et al. [36], to solve this multi-objective optimization
problem one can use bilevel linear programming coupled with evolutionary algo-
rithms, namely stochastic optimization methods that simulate the process of natu-
ral evolution. Evolutionary algorithms are well suited to multi-objective problems
because they can generate multiple Pareto-optimal solutions after one run and can
use recombination to make use of the similarities of solutions [35]. The input to the
evolutionary algorithm is a set of arrays, also called individuals, representing po-
tential solutions to the problem. These arrays are then ranked based on the values
of their objective functions. Potential optimal solutions are generated by retaining
the best individuals and by generating new individuals through the use of variation.
This process is continued until no further improvements are detected on the Pareto
front. The population size and the number of populations used with this algorithm
were 140 and 1400, respectively. To solve the linear programs, we used the Gurobi
solver (v5.6.3, Gurobi Inc.) [37].
To validate our choice of objectives, we conducted a genetic analysis using multi-
objective optimization. In this analysis, binary “knockout” vectors were created,
with each containing a 1 in the location of a gene set to be off [36]. This analy-
sis allowed us to determine how the growth of the organism changes in different
environments, when genes may be turned on or off.
Robustness analysis
A facet of living organisms is their homeostasis, otherwise known as their ability
to remain robust to external and internal perturbations within a certain range.
External perturbations include changes in temperature or food supply while internal
perturbations include spontaneous mutations. The robustness of biological systems
is partly due to the presence of parallel metabolic pathways. Robustness represents
the insensitivity of a system to changes in system parameters.
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Global Robustness (GR) analysis can be used to survey the parameter space to
determine the region where the cell exhibits specific features. More specifically, we
perturbed the flux bounds of the metabolic model and observed the resulting effects
on biomass production. The perturbation function γ(ψ, σ) where γ applies noise σ,
assumed to be Gaussian, to the system ψ for the trial τ . As proposed in [38], a
robust trial is associated with a ρ of 1:
ρ(ψ, τ, φ, ) =
1, if |φ(ψ)− φ(τ)| ≤ 0, otherwise (6)
where  is the robustness threshold. The GR was defined as the percentage of trials
determined to be robust. We arbitrarily defined  to be 1% of the metric φ(ψ) and
we arbitrarily limited the noise to 1% of the perturbed variable φ.
Incorporating transcriptomic and codon usage data in genome-scale models
To increase the reliability of the model, gene expression data was added to the
FBA framework. To relate this gene expression data to protein abundance, codon
usage bias data was also incorporated. The translation rate of a codon is deter-
mined in part by the speed of diffusion of a translationally-competent tRNA to the
ribosome. Because tRNAs are differentially abundant in the cell, codons pairing to
high-abundance tRNAs are translated faster than those pairing to low-abundance
tRNAs. Although synonymous codons produce the same amino acid sequence, they
can alter the translation speed and the protein expression levels depending on the
abundance of their associated tRNA [39]. Studies have revealed that a large codon
bias generally resulted in higher protein expression levels [18, 19]. Therefore, the
inclusion of codon bias can help improve the metabolic model predictions by helping
link gene expression levels to protein levels.
The codon usage table for C. difficile was obtained from the Kazusa Codon Usage
Database [40], which lists the frequency of different codons in the genome. The
weights for synonymous codons was determined as the ratio between the observed
frequency of the codon k and the frequency of the most preferred synonymous codon
for that amino acid:
wk =
fk
max(fm)
,where k,m ∈ [synonymous codons]. (7)
We obtained the mRNA sequence associated with the 834 genes of C. difficile from
UniProt [41]. The counts of different codons were determined for each mRNA se-
quence. To obtain a measure of the codon bias, we calculated the Codon Adapta-
tion Index (CAI) for each gene. The CAI represents the relative adaptiveness of
the codon usage of the relevant gene to the codon usage of highly expressed genes
[42]. The CAI ranges from 0 to 1, with a value of 1 indicating high expression and,
by correlation, high abundance of the associated protein. The CAI represents the
geometric mean of the weights corresponding to the codons in the sequence:
CAI = e
[
1
L
L∑
l=1
ln(wk(l))
]
, (8)
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where L is the number of codons in the genes and wk(l) is the weight associated
with codon type k for lth codon along the length L of the gene. Because a large
codon bias has been shown to result in higher protein expression levels, the gene
expression data gt for each gene t was scaled by CAI such that genes with the low
codon bias had lower expression g′t:
g′t = gt · (CAIt). (9)
Each of the reactions in the metabolic model depends on a gene set, which is
represented through the use of AND/OR operators. In this formulation, if a gene
set is composed of two genes and an AND operator, both genes are required to
carry out the corresponding reaction. On the other hand, if two genes connected
by OR, one gene is sufficient in carrying out the reaction. This formulation can
be transformed to derive the gene set expression GSEj for gene set j of reaction
j from the expression of individual genes g′t, which in our case has been scaled
by their respective codon usage. When two genes are connected through an AND
operator, the gene set expression for reaction i, gi, is the minimum of the scaled
expression of the individual genes t making up the gene set. The gene set expression
for two genes connected by an OR operator is the sum of the scaled expression of
the individual genes. In each reaction of the model, to map the gene set expression
into a specific condition of the model, we used the piecewise muliplicative function
h and the associated hj was adopted as a multiplicative factor for the flux bounds
[43] :
vLj h(GSEj) ≤ vj ≤ vUj h(GSEj),
where
h(GSEj) =
(1 + |log(GSEj)|)
GSEj−1
|GSEj−1| if GSEj ∈ R+ \ {1}
1 if GSEj = 1
(10)
The function h was chosen because at high mRNA abundance, an increase in mRNA
abundance has been found to produce a relatively small increase in the protein
synthesis rate. On the other hand, at low mRNA abundance, an increase in mRNA
abundance has been found to produce a large increase in the protein synthesis rate
[44].
Finally, we validated our context-specific metabolic models by incorporating
codon usage and differential gene expression data into our model. We then compared
trends in our models’ biomass predictions to literature on the bacterium.
Prediction of therapeutic targets
Essential gene analysis
For each gene in the model, essential gene analysis involved removing reactions
catalyzed by the gene or by a complex involving that gene and then using FBA
[20] to predict growth. Genes were considered essential if following their removal,
the predicted maximum growth rate was zero. The C. difficile R20291 (ribotype
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027), for which gene essentiality data was available for comparison with our in
silico results, had been grown on Tryptone-Glucose-Yeast Extract (TGY) broth.
To approximate this medium, we used the complex medium defined by Larocque et
al. during essential gene analysis of iMLTC806cdf [13].
Pathway-oriented sensitivity analysis
The growing research attention on metabolic pathways, rather than on specific
reactions, is motivated by novel methods that allow for a better understanding of
the functionality of complex webs of metabolic reactions. To date, much of the study
of metabolic pathways, their crosstalks, and their role in the overall metabotype has
been carried out with statistical and model-based approaches [45, 46].
Sensitivity analysis is used to identify model inputs that have a large influence
on the model outputs. To find the metabolic pathways that have the largest effect
on the outputs of iMLTC806cdf and icdf834, we used Pathway-oriented Sensitiv-
ity Analysis (PoSA) [36]. PoSA involves genetically manipulating the metabolic
model to find the sensitive pathways, which make a large impact on model out-
puts. In other words, we perturbed pathways by mutating the genes that govern
their biochemical reactions and analyzed the result on the outputs. In the knock-
out vector y = {b1, b2, ..., bs, ..., bp}, bs represents the perturbations on the genes
governing the metabolic pathway s, where |bs| = Ws (number of genes partaking in
the sth pathway). Because the gene knockouts are represented through the use of
binary variables, we perform combinatorial perturbations, namely the bits in bs are
switched from 0 to 1 or from 1 to 0; note that if a gene in bs is set to 1, this gene
is knocked-out in the model.
According to [36], the Pathway Elementary Effect (PEE) for the genetic pertur-
bation bs can be defined as follows:
PEEs =
∥∥∥F (b1, b2, ..., b˜s, ..., bp)− F (y˜)∥∥∥
∆s
, (11)
where b˜s represents the genetic manipulation of the input bs; y˜ is the mutation
carried out on the knockout vector y; F (y) is the vector v of fluxes as produced by
the model; finally, ∆s is a scale factor defined as:
∆s =
1
Ws
Ws∑
i=1
b˜s(i), s = 1, ..., p. (12)
Next, the sensitivity indices µ and σ are determined by calculating the mean and
the standard deviation of the distribution of the PEE for each input. Pathways
with a large µ have a large influence on the output. A large σ indicates an input
whose influence highly depends on the value of other inputs. By perturbing the
genes through the use of knockouts and comparing the outputs of the model with
and without the genetic manipulations, we detected the most sensitive pathways of
the metabolic models.
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Calculation of flux control coefficients
PoSA provides valuable information on sensitive pathways that can be targeted by
therapies, but often more specific drug target predictions are desired. To understand
how a metabolic pathway is controlled and can be altered, its control structure has to
be determined. The flux control coefficient [47] is the flux vydh through a particular
reaction, catalyzed by enzyme ydh, of the metabolic pathway with respect to the
concentration xxase of an enzyme xase:
C
vydh
xxase =
∂vydh
∂xxase
· xxase
vydh
=
∂ ln vydh
∂ lnxxase
(13)
In our calculations, the enzyme concentration was assumed to be equal to the gene
expression level adjusted by CAI. When calculating the flux control coefficients,
we considered a 1% perturbation in the enzyme concentration xxase. Flux control
coefficients provide a quantitative measure of the degree of control an enzyme exerts
on a metabolite flux and can quantitatively substitute for the qualitative concept of
essential gene [48]. Thus, they can be used to identify steps that should be modified
to achieve a successful alteration of the flux in outputs of clinical (e.g. drug therapy)
relevance.
Analysis of cDNA microarrays
We used microarray analysis to determine the combination of genes which were up-
regulated or down-regulated in different environmental conditions. We used Limma
[49], a package in Bioconductor 3.1, for statistical analysis of gene expression. We
preprocessed the data through background correction, within-array normalization,
and between-array normalization. After normalization, we used filtering to remove
probes that did not appear to be expressed in any of the experimental conditions.
Next, we used linear models to analyze the microarray data. To conduct statistical
analysis and assess differential expression, we used an empirical Bayes method to
modulate the standard errors of the log-fold changes. To test for the comparisons
of interest, we used an analysis of variance (ANOVA) model.
Results and discussion
Expansion and modification of iMLT806cdf to icdf834
The genome of C. difficile strain 630 is composed of a circular chromosome of
4,290,252 bp coding for 3,968 open reading frames (ORFs), along with a plas-
mid containing 7,881 bp coding for 11 ORFs [50]. The modified metabolic network
draft contains 21% of the ORFs present in the chromosomal genome of the bac-
teria with 834 ORFs, a modest improvement upon iMLTC806cdf, which contains
806 ORFs, as shown in Table 1. Our expanded metabolic network also consists
of 807 metabolites and 1227 reactions. The final version of the network is avail-
able as an SBML file and as an Excel file that indicate the reactions, metabo-
lites, genes, and compartments involved in the metabolic network, along with refer-
ences to literature that support additions or modifications to the existing network.
The new network has two additional dead-end metabolites as compared with those
found in iMLTC806cdf. The Excel and SBML file, along with the the justifica-
tion for keeping the dead-end metabolites in the model, have been uploaded to
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http://github.com/ssahebkashaf/Peptoclostridiumdifficile630. The code for all of
the analyses employed in our work is also freely available on this repository.
We repeated analyses previously conducted by Larocque et al. to validate
iMLTC806cdf [see Additional file 1]. Namely, we compared the ability of icdf834 and
iMLTC806cdf to identify essential amino acids and metabolizable carbon sources.
The removal of amino acids that were not found to be essential or to affect growth,
did not affect model-predicted biomass production in both models. Moreover, no
biomass was produced in the absence of essential amino acids (cysteine, leucine,
isoleucine, proline, tryptophan and valine) [51] in both models. Therefore, similar
to the previous network, our network is able to account for the essentiality of various
amino acids on the growth of C.difficile.
With regards to carbon sources, both models were able to correctly predict a range
of carbon sources that are utilized by the bacterium. Moreover, the bacterium was
able to generate biomass in the absence of other carbon substrates, such as fructose,
mannose, mannitol, and sorbitol. This finding is consistent with literature, which
maintains that C. difficile is not restricted to metabolizing sugars and can ferment
other compounds, even amino acids, to obtain both its carbon and energy [52].
Validation of metabolic models
Genetic analysis using multi-objective optimization
Our modeling approach is intended to simulate the conflicting objectives faced by
the bacterium, where optimal performance in one objective coincides with sub-
optimal performance in another objective. We used a knockout parameter space to
find the genetic designs that would optimize the two objectives. In Figure 2, we show
the areas of objective space discovered by the genetic algorithm during the genetic
analysis from the first generation to generation 1400. The optimization algorithm
adaptively moves to regions that maximize biomass while minimizing the total in-
tracellular flux, as evident in the curvature of the plot in Figure 2. After conducting
the genetic analysis, the Pareto front, shown in black in the inset of Figure 2, was
determined. The Pareto front is the set of nondominated solutions that represents
the range of phenotypes resulting from different trade-offs between the two objec-
tives. The presence of a Pareto front, as opposed to a singular dominated solution,
aligned with our a priori expectations regarding the metabolic plasticity inherent
to the bacterium [53]. Our findings, along with previous literature on the choice of
objectives, supported our choice of objectives to model C. difficile’s metabolism.
Robustness analysis
We gauged the robustness of our model by determining the change in the maximal
biomass flux in response to different perturbations. Global Robustness (GR) analy-
sis revealed that the biomass production was fully robust to perturbations for a flux
bound perturbation (σ) and a tolerance () of 1% [see Additional file 2]. The GR
falls when σ is increased or  is decreased. This facet of the bacterium’s metabolism
was biologically relevant as bacteria such as C. difficile are able to grow despite
small fluctuations in their physical environment. Robustness analysis illustrated
that the global behavior of our metabolic model matches our expectations from
biological rationale and supported the use of our models to predict the behavior of
the bacterium in different environments.
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Changes in C. difficile’s growth in different conditions
We obtained the relevant microarray datasets from the Gene Expression Omnibus
(GEO) database [54] under the accession numbers GSE22423 and from the ArrayEx-
press database [55] under the accession numbers E-GEOD-37442 and E-BUGS-56.
Context-specific models for C. difficile were generated by incorporating gene ex-
pression data obtained for the bacterium in different environmental conditions. To
improve the reliability of the model, we also integrated codon usage data. Model
predictions of these context-specific models were compared to expectations about
the organism’s behavior from literature.
Previous work suggests that sub-MIC concentrations of amoxicillin, metronida-
zole, and clindamycin slowed growth of toxigenic C. difficile as compared with the
controls [56]. To test these findings in silico, we incorporated gene expression lev-
els of C. difficile in response to sub-MIC levels of different antibiotics into our
model. As compared with the C. difficile grown on BHI broth, toxigenic strains of
C. difficile grown on sub-inhibitory concentrations of antibiotics exhibited reduc-
tions in their biomass, with those grown on amoxicillin showing the smallest growth
(as shown in Table 2). This finding is supported by literature [57] that has shown
that in vitro, amoxicillin is effective against C. difficile. These findings have lead to
speculations that in vivo, this antibiotic is effective aginst vegetative forms of the
bacterium but not against C. difficile spores [58]. Another potential explanation is
that this broad-spectrum antibiotic may impair the intestinal microflora in a way
that supports proliferation of C. difficile.
Additionally, the decline in biomass production following heat shock from 30◦C
to 43◦C shown in Table 2 could be due to the general stress response employed
by the bacterium. The heat shock response of C. difficile has been found to be
involve gene clusters homologous to E. coli heat-shock operons [59]. The heat shock
response in E. coli has been found to be associated with a decrease in central carbon
metabolism and a decline in cellular growth [60]. Literature on related bacteria
is thereby in agreement with the model’s prediction of a significant reduction in
growth in C. difficile following the heat shock. Additionally, according to the work
of Dubois et al, the supplementation of 10mM cysteine to the medium did not affect
C. difficile’s growth [61]. After integrating the microarray data from their work, we
found that our in silico findings agreed with their experimental results.
Validation of the findings of our context-specific metabolic models against the
literature on the bacterium showed that metabolic models allow for an enriched
view of omic data and may be valuable tools for better understanding the behavior
of C. difficile in different conditions.
Prediction of therapeutic targets
Gene essentiality analysis
Essential genes have been cited as promising targets for development of new antimi-
crobials due to their importance for bacterial survival [62]. Using FBA, we performed
an in silico gene deletion study to predict potential essential genes that may lead
to the identification of new drug targets. This analysis had already been conducted
for iMLTC806cdf based on a 5% threshold, and gene essentiality results had been
compared to genes deemed essential for B. subtilis, for which this data had been
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available [13]. We performed gene essentiality analysis for both iMLTC806cdf and
icdf834 and validated our results using recently available literature on the essential
genes of the C. difficile R20291 (ribotype 027) [63]. While iMLTC806cdf predicted
48 essential genes and had a 86.5% accuracy in predicting gene essentiality, icdf834
predicted 46 essential genes and had a 92.3% accuracy [see Additional file 3].
Pathway-oriented sensitivity analysis and flux control coefficients
For our PoSA analysis, we chose the gene expression profile of the bacterium when
grown on BHI broth. Each pathway was assessed through random perturbations of
its reactions, and the average perturbation µ and the standard deviation σ were
computed as a result. We performed the pathway-based sensitivity analysis and
identified sensitive pathways before and after modifying the metabolic model as
shown in Figure 3. The pathway with the largest µ, and thereby the greatest con-
trol on biomass production or growth in both iMLTC806cdf and icdf834 is the
valine, leucine, and isoleucine metabolism pathway. These three amino acids are es-
sential to the bacterium and their metabolism was also expected to be essential. The
second most sensitive pathway is alanine, aspartate, and glutmate metabolism in
iMLTC806cdf and glycolysis/gluconeogenesis in icdf834. Additional sensitive path-
ways in icdf834 include pyrimidine metabolism and pyruvate metabolism. Model
findings suggest that therapies against infection may likely be more effective if they
target key enzymes in these sensitive pathways.
To find more specific therapeutic targets, flux control coefficients for enzymes
on biomass production in the metabolic model were determined and compared for
BHI broth (E-BUGS-56), cysteine supplementation (GSE22423), and heat shock
(E-GEOD-37442) gene expression data. The four enzymes with largest flux control
coefficients in each condition are shown in Figure 4, while the complete list of
flux control coefficients in different conditions has been uploaded to the public
repository. These flux control coefficients were interestingly involved in pathways
deemed sensitive during PoSA. These enzymes varied amongst the four conditions,
suggesting that access to the in vivo gene expression profile of C. difficile can be
used to predict better drug targets for patients. Therapies aimed at reducing growth
of C. difficile should target enzymes with high flux coefficients as, according to our
model, their activity is most closely tied to biomass production.
Conclusion
In this study, we expanded the existing metabolic network for C. difficile and used
it to create context-specific metabolic models of its metabolism that allow us to un-
derstand how the bacterium alters its metabolism depending on its environment. To
predict the bacterium’s behavior in different environmental conditions, the model
was integrated with transcriptomic and codon usage data to generate reliable and
context-specific metabolic flux distributions. We validated the model by conducting
robustness and sensitivity analyses. We further assessed its predictive potential by
comparing model predictions with published experimental data to gauge the con-
sistency of model findings with the current knowledge of C. difficile’s metabolism.
Through this literature-based validation, we found that the model is a valuable tool
for qualitatively understanding the behavior of the bacterium in different settings.
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The model can also be used to find potential therapeutic targets by allowing for
determination of essential genes and context-specific sensitive pathways and flux
control coefficients.
Context-specific metabolic models can allow for a better understanding different
medically-relevant conditions (eg. pre-infection, post infection) and can be contin-
uously refined by integrating novel information regarding C. difficile’s metabolism.
Our model can be used by biomedical researchers to study the bacterium and devise
targeted treatments. Our approach can also be scaled-up to simulate the interactions
between the gut microbiota and the host using a bottom-up modeling approach.
By accounting for the gut microbiota-host interactions, we can construct a whole
gut model response to infections and other inflammatory events, paving the path
towards more informed and effective treatments.
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Figures
Figure 1 Framework for modeling the metabolism of C.difficile. The updated metabolic
network of the bacterium was used to create a metabolic model that was assessed using sensitivity
and robustness analyses. Integrating gene expression and codon usage data yielded
context-specific metabolic models that were evaluated against biological rationale and found fit
for clinical applications. The augmented metabolic models were then used to identify potential
therapeutic targets using gene essentiality analysis, PoSA, and flux control coefficient calculations.
Figure 2 Genetic analysis using multi-objective optimization Regions of objective space explored
by the optimization algorithm for the objectives of maximization of biomass and minimization of
total intracellular flux. Solutions are represented by progressively warmer colors depending on the
time step of the algorithm in which they had been adaptively generated from the initial point. The
Pareto front is shown in black in the inset.
Figure 3 PoSA was used to compare the most sensitive pathways of iMLTC806cdf and
icdf834. The iMLTC806cdf model is composed of 48 metabolic pathways and the icdf834 model
is composed of 50 metabolic pathways. Biomass production is most sensitive to pathways with
higher calculated µ.
Figure 4 Genes encoding the enzymes with the largest flux control coefficients for biomass
production in different conditions (top). Table of metabolic pathway(s) hosting the genes and
of gene descriptions [64] (bottom). A flux control coefficient of 1 implies full control of the
metabolite flux by the associated enzyme.
Tables
Additional Files
Additional file 1 — Carbon source usage, carboxylic acids secreted, and essential amino acids in icdf834 as
compared with iMLTC806cdf and literature.
Additional file 2 — GR of biomass production in icdf834 to internal and external perturbations.
Additional file 3 — Gene essentiality analysis of icdf834 and iMLTC806cdf.
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Table 1 Comparison of the metabolic network iMLTC806cdf published by [13] and the modified and
expanded network icdf834
Features Number
Genomic Information of C. difficile
Genome size (bp) 4,290,252
Open reading frames 3968
Reconstructed models
iMLTC806cdf icdf834
Metabolites 703 807
Reactions 1091 1227
Open reading frames 806 834
Table 2 Percent change in model-predicted biomass production (growth) of C. difficile in different
conditions. The microarray data for each condition was obtained from the GEO or ArrayExpress
databases, using the specified accession numbers. The differential gene expression levels obtained
from analysis of this microarray data was used to make a metabolic model for each condition. These
context-specific metabolic models were used to predict change in biomass production for each
condition compared with the control of each microarray dataset
Microarray Data Accession Number/Database Condition % change in biomass (h−1)
E-GEOD-37442/ArrayExpress
Heat shock from 30◦C to 43◦C ↓ 24.3%
E-BUGS-56/ArrayExpress
Sub-MIC level of amoxicillin ↓ 27.4%
Sub-MIC level of clindamycin ↓ 16.6%
Sub-MIC level of metronidazole ↓ 2.3%
BHI broth ↑ 1.0%
GSE22423/GEO
Supplementation of 10mM cysteine ↑ 1.1%
